Financial Performance - The company reported a loss attributable to owners of the company of HKD 3.1 million for the nine months ended December 31, 2022, compared to a profit of HKD 3.2 million for the same period in 2021, primarily due to a decrease in revenue of approximately HKD 8.3 million or 20.5%[13] - Basic loss per share for the period was HKD 0.79, compared to a basic earnings per share of HKD 0.81 for the same period last year[13] - The company’s total revenue for the nine months ended December 31, 2022, was HKD 31.9 million, a decrease from HKD 40.2 million in the same period last year[58] - The group recorded a net loss of HKD 3.14 million for the nine months ended December 31, 2022, compared to a profit of HKD 3.22 million in the same period of 2021[77] - The group's revenue decreased by HKD 8.3 million or 20.5% to HKD 31.9 million for the nine months ended December 31, 2022, compared to HKD 40.2 million for the same period in 2021[83] Revenue Breakdown - Revenue from medical consultation services for the three months ended December 31, 2022, was HKD 227,000, a decrease of 26% from HKD 306,000 in the same period of 2021[62] - Revenue from prescription and dispensing services for the nine months ended December 31, 2022, was HKD 6.94 million, down 10.6% from HKD 7.76 million in the same period of 2021[62] - Revenue from medical consultation services, prescription and dispensing services, and treatment services were HKD 0.7 million, HKD 6.9 million, and HKD 24.3 million, respectively, accounting for 2.3%, 21.7%, and 76.0% of total revenue[108] Cost and Expenses - The cost of inventory for the group was HKD 6.1 million and HKD 6.2 million for the nine months ended December 31, 2022, and 2021, respectively, representing 19.0% and 15.5% of the group's revenue for the respective periods[15] - Other expenses decreased by HKD 0.7 million or 10.6% compared to the nine months ended December 31, 2021, which amounted to HKD 6.5 million[17] - Employee costs decreased by HKD 1.8 million or 10.8% to HKD 15.5 million for the nine months ended December 31, 2022, primarily due to reduced salaries and bonuses[38] Future Outlook - The company maintains a cautious optimism regarding future performance, anticipating a significant rebound in local consumer sentiment and sales due to the lifting of COVID-19 restrictions[14] - The company aims to continue providing high-quality medical skin care services and products while seeking new business opportunities to enhance its market position and maximize returns for investors[14] - The group believes that introducing new services and products is one of the key drivers for business growth and maintaining competitiveness[109] Market Presence - The company’s revenue from external customers is primarily derived from Hong Kong, indicating a focused market presence[28] - The company has a solid customer base, with most clients having been with the company for over five years, contributing to its revenue stability[12] - The group did not have any individual customer contributing more than 10% of total revenue during the nine months ended December 31, 2022[9] Operational Developments - The company has implemented measures to enhance online consultation services and e-commerce platforms for skincare products in response to the pandemic[35] - The group continues to face intense market competition and the negative impact of the COVID-19 pandemic[80] - The group will continue to conduct market research on the latest products, skills, and medical instruments and technologies[109] Governance and Compliance - The audit committee currently consists of two independent non-executive directors, ensuring compliance with GEM listing rules[123] - The company has established an audit committee and has developed a written terms of reference in accordance with GEM listing rules[123] - The company is committed to appointing sufficient independent non-executive directors to meet the minimum requirements of GEM listing rules within three months from November 15, 2022[121] Other Financial Information - The company did not recommend the payment of an interim dividend for the nine months ended December 31, 2022, consistent with the previous year[31] - Interest income from bank deposits for the nine months ended December 31, 2022, was HKD 233,000, an increase of 6.4% from HKD 219,000 in the same period of 2021[64] - The group received government grants amounting to HKD 829,000 for the nine months ended December 31, 2022[64] - The group reported a foreign exchange loss of HKD 1.52 million for the nine months ended December 31, 2022, compared to a gain of HKD 432,000 in the same period of 2021[64] - The group has not recognized any provision for Hong Kong profits tax due to estimated taxable profits being offset by estimated prior tax losses[86] - The company has not purchased, sold, or redeemed any of its listed securities during the nine months ended December 31, 2022[47] - As of December 31, 2022, the group's current liabilities net amount was HKD 3.2 million, primarily from contract liabilities of HKD 20.1 million[61] - As of December 31, 2022, no share options were exercised or cancelled, and 4,000,000 share options expired[95] - The company has adopted a share option scheme to reward eligible individuals for their contributions to the group[23]
密迪斯肌(08307) - 2023 Q3 - 季度财报